Thursday, November 30, 2023 at 2-3 pm ET                 Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

This webinar will discuss the burden of disease in hemophilia A, provide an overview of current methods of half-life extension for factor VIII replacement therapies, and introduce efanesoctocog alfa [link to prescribing information] as a first-in-class, high-sustained factor VIII replacement therapy. The webinar will present the results of the Phase 3 XTEND-1 study [link to XTEND-1 manuscript] and the Phase 3 XTEND-Kids study. There will be a live Q&A to allow for interactive discussion.

Learning Objectives

At the completion of this webinar, participants should be able to:

• Describe the burden of disease in hemophilia A and the need for frequent infusions of factor VIII replacement therapy in patients with severe disease.
• Explain the potential benefits of targeting higher factor VIII activity levels.
• Understand the molecular structure and mechanism of half-life extension of efanesoctocog alfa.
• Understand the results of the pivotal XTEND-1 and XTEND-Kids studies from a payer perspective.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

Sanofi Specialty Care Medical Value & Outcomes

For individuals from the media/press interested in attending, please email media@amcp.org.